Your browser doesn't support javascript.
loading
Appearance of acute myelogenous leukemia [AML] in a patient with breast cancer after adjuvant chemotherapy: case report and review of the literature
Iranian Journal of Cancer Prevention. 2015; 8 (2): 125-128
in English | IMEMR | ID: emr-161876
ABSTRACT
Acute Myelogenous Leukemia [AML] is an aggressive hematologic malignancy that cause by abnormal proliferation and accumulation of hematopoietic progenitor cells. A 37-year-old woman referred to oncologic clinic with a self-detected mass and pain in her left breast. The stage of tumor was IIIA. She was treated with the combination of anthracycline and cyclophosphamide for four courses, followed by four courses of paclitaxel with trastuzumab for one year. After 18 months of the first treatment for breast cancer, her bone marrow biopsy was compatible with AML-M2. Here, we are reporting a young woman case with breast cancer that developed AML malignancy during short interval of therapy
Subject(s)
Search on Google
Index: IMEMR (Eastern Mediterranean) Main subject: Breast Neoplasms / Review Literature as Topic / Chemotherapy, Adjuvant / Paclitaxel / Anthracyclines / Cyclophosphamide / Antibodies, Monoclonal, Humanized Type of study: Case report Limits: Female / Humans Language: English Journal: Iran. J. Cancer Prevention Year: 2015

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Index: IMEMR (Eastern Mediterranean) Main subject: Breast Neoplasms / Review Literature as Topic / Chemotherapy, Adjuvant / Paclitaxel / Anthracyclines / Cyclophosphamide / Antibodies, Monoclonal, Humanized Type of study: Case report Limits: Female / Humans Language: English Journal: Iran. J. Cancer Prevention Year: 2015